|

Lung Cancer Clinical Trials in Indianapolis, IN

54 recruiting studies within 50 miles

Phase
Trial Phase Dist.
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])Phase 3<1 mi
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerPhase 2/3<1 mi
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialPhase 3<1 mi
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung CancerPhase 3<1 mi
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking AbilityPhase 3<1 mi
A Study of LY4175408 in Participants With Advanced CancerPhase 1<1 mi
A Phase I/II Study of VLS-1488 in Subjects With Advanced CancerPhase 1/2<1 mi
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung CancerPhase 2<1 mi
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor MalignanciesPhase 1/2<1 mi
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1Phase 3<1 mi
GEMINI-NSCLC: NSCLC Biomarker Study—<1 mi
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung CancerPhase 2<1 mi
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerPhase 3<1 mi
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsPhase 1/2<1 mi
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsPhase 1<1 mi
Pediatric Long-Term Follow-up and Rollover StudyPhase 4<1 mi
Veterans Affairs Lung Cancer Surgery Or Stereotactic RadiotherapyN/A<1 mi
Open-Label Study of BBO-10203 in Subjects With Advanced Solid TumorsPhase 1<1 mi
TTX-080 HLA-G Antagonist in Subjects With Advanced CancersPhase 1<1 mi
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid TumorsPhase 1/2<1 mi
Pilot Randomized Clinical Trial of Informational Support Versus Spiritual CareN/A<1 mi
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung CancerPhase 1<1 mi
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)Phase 2<1 mi
Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLCPhase 1/2<1 mi
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsPhase 1<1 mi
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)Phase 2<1 mi
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanPhase 1<1 mi
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid TumorsPhase 1<1 mi
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine CancersPhase 2<1 mi
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)Phase 3<1 mi
A Study of VET3-TGI in Patients With Solid TumorsPhase 1<1 mi
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialPhase 3<1 mi
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cmPhase 2<1 mi
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)Phase 2<1 mi
Increasing Equity in Lung Cancer ScreeningN/A<1 mi
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLCPhase 3<1 mi
A Study of Sigvotatug Vedotin in Advanced Solid TumorsPhase 1<1 mi
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)Phase 2/3<1 mi
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsPhase 1/2<1 mi
Rapid Autopsy Protocol for Patients With Small Cell Lung Cancer—<1 mi
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung CancerPhase 2<1 mi
Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung CancerN/A<1 mi
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With OsteosarcomaPhase 3<1 mi
MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung CancerPhase 2<1 mi
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Phase 3<1 mi
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)Phase 2<1 mi
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the LungsPhase 1/2<1 mi
Repositioning Immunotherapy in VetArans With Lung CancerPhase 2<1 mi
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerPhase 3<1 mi
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerPhase 3<1 mi
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D MutationPhase 1/2<1 mi
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid TumorsPhase 1<1 mi
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsPhase 321 mi
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Phase 221 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.